Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
83
resultados
Última actualización
02/05/2026 [06:45:00]
Resumen de: US20260115287A1
Provided herein are uses of T cells, e.g., chimeric antigen receptor (CAR) T cells, for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma) wherein the subject being treated has previously received a stem cell transplant.
Resumen de: WO2026090567A1
Provided herein are, inter alia, novel antibodies that bind to fms-like tyrosine kinase 3 (FLT3) thereby effectively targeting cells expressing FLT3. The antibodies provided herein may be used, inter alia, for therapeutic cancer applications, including, in some embodiments, treatment of multiple cancer types, which may include acute myeloid leukemia (AML), lymphoblastic leukemia (ALL), lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, renal cancer, or glioblastoma.
Resumen de: WO2026088163A1
Provided herein is an immune cell expressing a recombinant IL-2 or IL-2 mutein, wherein the immune cell is a natural killer cells (e.g., a cord blood derived NK (CB-NK) cell) or a γδ T cell, and wherein the IL-2 mutein has reduced binding to IL2 receptor (IL2R) (e.g., IL2Rβ). These immune cells can also be used in conjunction with cells genetically engineered with chimeric antigen receptors (CARs). Also provided are methods of modulating immune function by administering said immune cell, and methods of treating cancer, for example, acute myeloid leukemia.
Resumen de: WO2026086735A1
The present invention provides a heteroaryl compound having a structure represented by formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, as well as a pharmaceutical composition thereof, and a use thereof. The heteroaryl compound and the pharmaceutically acceptable salt and isomer thereof provided by the present invention can effectively inhibit the activity of RET kinases, including wild-type and various mutant RET kinases, especially RET kinases having G810C and G810R mutations, can further regulate the activation of multiple downstream pathways, and can be used to prepare drugs for preventing and treating various diseases related to abnormal RET kinase expression, such as leukemia and other tumors.
Resumen de: WO2026085569A1
The present disclosure relates to chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain comprising a modified single chain variable fragment (scFv) that specifically recognises lambda myeloma antigen (LMA). The present disclosure also relates to a polynucleotide encoding the CAR, vectors, genetically modified cells and uses thereof.
Resumen de: WO2026090579A1
Provided herein are methods of treating smoldering multiple myeloma in a subject in need thereof. In some embodiments, the method comprises administering ciltacabtagene autoleucel. In some embodiments, the method comprises administering ciltacabtagene autoleucel to a subject, wherein the subject achieves minimum residual disease (MRD) negative status by about 28 days after administration of ciltacabtagene autoleucel.
Resumen de: WO2026090536A1
In some aspects, the present disclosure relates to methods of treating an NK cell or T-cell lymphoma or leukemia (e.g., a CTL or LGLL) in an individual in need thereof, comprising administering an antibody that specifically binds to human CD94 (anti-CD94 antibody) at one or more doses of from about 0.3 mg/kg to about 10 mg/kg. In other aspects, the present disclosure relates to methods of reducing likelihood of experiencing a severe reaction to a treatment involving an anti-CD94 antibody, improving safety of a treatment involving an anti-CD94 antibody, and/or reducing likelihood of experiencing tumor lysis syndrome in response to a treatment involving an anti-CD94 antibody. Related uses, kits, and articles of manufacture are further provided.
Resumen de: US20260117176A1
Multiplex base edited chimeric antigen receptor (CAR)-expressing immune effector cells (e.g., T or NK cells) having increased resistance to development of an exhausted phenotype (e.g., increased cytotoxicity, proliferation, survival, and/or cytokine production) after repeated or continuous stimulation by an antigen relative to unedited CAR immune effector cells, compositions containing the cells, methods for the preparation of the cells, and methods for use of the cells in treating a disease or disorder (e.g., an autoimmune disorder or a neoplasia, such as a leukemia).
Resumen de: US20260118360A1
The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.
Resumen de: US20260115223A1
This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).
Resumen de: US20260116982A1
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. The present invention provides CARs comprising a CD1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.
Resumen de: WO2024263845A1
Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
Resumen de: WO2024263861A2
There is provided a method of treating chronic lymphocytic leukemia (CLL) comprising the administration of a therapeutically effective amount of a FLT3 inhibitor and, optionally, one or more additional agents which are suitable for the treatment of CLL to a patient in need thereof.
Resumen de: WO2025080137A1
The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of minimal numbers of leukemia/lymphoma cells in chronic lymphocytic leukemia (CLL) patients after therapy has started. Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in CLL, the reagent composition comprising a panel of at least six antibodies conjugated to a detectable label, the panel comprising antibodies directed against the markers CD180, CD38, CD81, CD19, CD27 and CD5.
Resumen de: WO2026083308A2
Disclosed herein are methods for determining whether a subject is suffering from Waldenström macroglobulinemia (WM) or a precursor condition thereof, or multiple myeloma (MM) or a precursor condition thereof. These methods comprise determining, in a sample obtained from the subject, data indicative of the proportions of two or more immune cell populations. Methods of monitoring a subject with WM, or a precursor condition thereof, are also disclosed. These methods comprise determining in tumor cells obtained from a sample obtained from the subject and a reference sample expression of two or more gene expression signatures which indicate whether the subject is at risk of disease progression.
Resumen de: WO2026084962A2
Disclosed herein is a composition of a compound that has superior pharmacokinetics and pharmacodynamics as compared to conventional interferon. In addition, a method to use such composition to treat human T-cell leukemia virus type 1 (HTLV-1) associated diseases are also disclosed.
Resumen de: WO2026084950A1
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
Resumen de: US20260109777A1
0000 The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.
Resumen de: WO2026083265A1
The present invention is directed to (phthalazin-3-yl)amine derivatives of formula (I) as BFL-1 inhibitors for use in methods of treatment of leukemias, lymphomas and other cancers.
Resumen de: US20260108608A1
0000 The present invention relates to immune cells co-expressing a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain and IL-15, and a composition for preventing or treating cancer comprising the same as an active ingredient. The immune cells of the present invention not only exhibit synergistic tumor cell-killing activity by co-expression of the chimeric antigen receptor and IL-15, but also have significantly improved viability and in vitro proliferation rate, and thus they may be used as an efficient anticancer cell therapy. In particular, the immune cells of the present invention, when expressing a chimeric antigen receptor targeting CD5, may be applied as an effective therapeutic composition for various CD5-positive tumors, including lymphocytic leukemia.
Resumen de: US20260108534A1
Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.
Resumen de: WO2026083263A1
The present invention is directed to (isoquinolin-1-yl)amine derivatives of formula (I) as BFL-1 inhibitors for use in methods of treatment of leukemias, lymphomas and other cancers.
Resumen de: AU2024354261A1
Disclosed herein are high throughput synthetic methods for the deliberate and prospective discovery of molecular glues which can be used to form composite protein-ligand surfaces that facilitate interfacial binding to other proteins over dispersed surfaces. In particular, this application discloses a high throughput approach using sulfur(VI) fluoride exchange (SuFEx) transformations and N-hydroxysuccinimide (NHS)-ester derived amide couplings to prospectively repurpose known ligands for a prolein-of-interest into degraders and compounds capable of inducing proximity to other proteins. Disclosed herein are methods of developing known ligands of a target protein into degraders of the target proteins. Further disclosed are methods of developing novel small molecule chromatin-competitive inhibitors of the eleven nineteen leukemia (ENL) YEATS domain into effective degraders of ENL.
Resumen de: AU2026202537A1
Abstract The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and a scFv 5 targeting CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention 10 targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B- cell lymphoma, leukemia and other diseases. pr
Nº publicación: WO2026083261A1 23/04/2026
Solicitante:
JANSSEN PHARMACEUTICA NV [BE]
Resumen de: WO2026083261A1
The present invention is directed to quinazoline derivatives of formula (I) as BFL-1 inhibitors for use in methods of treatment of leukemias, lymphomas and other cancer.
BOPI
Sede Electrónica
